- $19.79bn
- $20.19bn
- $982.02m
U.S. RESEARCH ROUNDUP- Adobe, Caseys General Stores, Oracle
U.S. STOCKS ON THE MOVE-Intel, Victoria's Secret, Super Micro
U.S. STOCKS ON THE MOVE-Novo Nordisk, Intel, Oracle
U.S. STOCKS ON THE MOVE-Enliven Therapeutics, DXC Technology, Humacyte
Guardant Health rises as FDA clears blood test for lung cancer drug use
Blood test added to US colorectal cancer screening options
Brief: FDA Approves New Guardant360 Liquid Cdx, The Largest FDA-Approved Liquid Biopsy Panel With A 100X Expanded Footprint
Judge sanctions law firm Quinn Emanuel, citing ethical lapses
U.S. RESEARCH ROUNDUP-Applied Materials, McDonald's, McKesson
Guardant Health raises 2026 revenue outlook after Q1 beat
Brief: Guardant Health Q1 Adjusted EPS USD -0.45 Vs. IBES Estimate USD -0.76
Brief: Guardant Health Receives FDA Approval For Guardant360® Cdx As A Companion Diagnostic For Arvinas And Pfizer’S Veppanu (Vepdegestrant) For Patients With Er+/Her2- Advanced Breast Cancer With Esr1 Mutations
U.S. RESEARCH ROUNDUP-Biogen, Equinix, Revolution Medicines
Brief: Guardant Health’S Infinityai Real-World Evidence Supports Approval Of Enhertu® For Previously Treated Patients With Her2-Positive Metastatic Solid Tumors In Japan
Brief: Guardant Health Launches Shield Multi-Cancer Detection (Mcd) Test In Multiple Markets In Asia With Manulife Partnership
U.S. RESEARCH ROUNDUP-Dollar General, Keysight Technologies, Teledyne Technologies
U.S. RESEARCH ROUNDUP-Dropbox, Etsy, Zscaler
Guardant Health Q4 revenue up 39% driven by oncology and screening
Brief: Guardant Health Q4 Adjusted EPS USD -0.5 Vs. IBES Estimate USD -0.7